Patents by Inventor Robert S. Schwartz

Robert S. Schwartz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11389652
    Abstract: A method includes receiving monitoring data from at least one sensing device coupled to a subject and analyzing the monitoring data to identify one or more physiologic parameters of the subject. The method also includes providing signaling to at least one stimulating device in response to the identified physiologic parameters, the signaling comprising instructions to apply a stimulus to the subject. The method further includes receiving additional monitoring data from the at least one sensing device, analyzing the additional monitoring data to identify one or more changes in the one or more physiologic parameters of the subject after application of the stimulus to the subject, and providing additional signaling to the at least one stimulating device, the additional signaling comprising instructions to modify the stimulus applied to the subject based on the identified changes in the one or more physiologic parameters.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: July 19, 2022
    Assignee: LifeLens Technologies, LLC
    Inventors: Landy Toth, Robert S. Schwartz, Beth Schwartz
  • Publication number: 20220218210
    Abstract: Methods and systems are provided for diagnosis and/or treatment of microvascular dysfunction, such as microvascular obstruction (MVO) by injecting volumetric flows into a vessel using an infusion system to arrest or reverse native antegrade flow, such that an equipoise value of volumetric flow rate and corresponding pressure may be determined, which in turn enables calculation of MVO, absolute hydrodynamic resistance, fractional flow reserve, coronary flow reserve, and other physiologic parameters in real-time or near real time.
    Type: Application
    Filed: January 10, 2022
    Publication date: July 14, 2022
    Applicant: CorFlow Therapeutics AG
    Inventors: Robert S. SCHWARTZ, Martin T. ROTHMAN, Jacques SEGUIN
  • Patent number: 11382687
    Abstract: Systems, methods and devices for controlled sympathectomy procedures for neuromodulation in the treatment of subjects having neoplastic conditions are disclosed. Systems, methods, and devices for interventionally treating a cancerous tumor and cancer related pain are disclosed.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: July 12, 2022
    Assignee: Autonomix Medical, Inc.
    Inventors: Landy Toth, Robert S. Schwartz
  • Publication number: 20220211328
    Abstract: Systems and methods are provided for monitoring and processing physiological signals (e.g., electrocardiogram signals) to detect and predict for possible dysfunction of an anatomical feature (e.g., cardiac dysfunction) or otherwise predict a likelihood of future cardiac dysfunction of the individual. For example, a system comprises a plurality of sensors, a physiological signal processing system, and a feature analysis system. The sensors are configured to monitor physiological signals from an individual that has undergone a medical procedure on an anatomical feature. The physiological signal processing system is configured to analyze the physiological signals and extract features from the physiological signals which are indicative of a function of the anatomical feature.
    Type: Application
    Filed: May 7, 2020
    Publication date: July 7, 2022
    Inventors: Landy Toth, Robert S. Schwartz, Jonathan G. Schwartz
  • Patent number: 11375959
    Abstract: A method includes obtaining monitoring data recorded by first and second devices, the first and second devices being attached to the subject at different first and second sties, respectively. The monitoring data comprises signals associated with at least one physiological parameter of the subject. The method also includes extracting one or more features of the signals recorded by the first and second devices during a transitionary period when the first and second devices simultaneously monitor the at least one physiological parameter of the subject. The method further includes generating at least one correlation parameter by analyzing the extracted features of the signals recorded by the first and second devices for at least a portion of the transitionary period, the at least one correlation parameter when applied to signals recorded by the second device at least partially compensating for relative changes in signals recorded by the first and second devices.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: July 5, 2022
    Assignee: LifeLens Technologies, LLC
    Inventors: Landy Toth, Robert S. Schwartz
  • Patent number: 11369780
    Abstract: Methods and devices that prevent stasis in the LAA by either increasing the flow through the LAA or by closing off or sealing the LAA. Increasing the flow is accomplished through shunts, flow diverters, agitators, or by increasing the size of the ostium. Closing off the LAA is accomplished using seals or by cinching the LAA.
    Type: Grant
    Filed: February 6, 2020
    Date of Patent: June 28, 2022
    Assignee: NXT Biomedical, LLC
    Inventors: Glen Rabito, Joseph Passman, Robert C. Taft, Stanton J. Rowe, Robert S. Schwartz, Alexander Siegel
  • Publication number: 20220192595
    Abstract: Systems, methods and devices for controlled sympathectomy procedures for neuromodulation in the treatment of subjects having neoplastic conditions are disclosed. Systems, methods, and devices for interventionally treating a cancerous tumor and cancer related pain are disclosed.
    Type: Application
    Filed: March 9, 2022
    Publication date: June 23, 2022
    Inventors: Landy Toth, Robert S. Schwartz
  • Publication number: 20220176087
    Abstract: Devices and methods of treating fluid retention caused by congestive heart failure or other conditions resulting in edema, lymphoedema, or significant fluid retention (e.g., deep vein thrombosis, cellulitis, venous stasis insufficiency, or damage to the lymphatic network) are described. Specifically, a treatment device is used to create a passage or cannula between the lymphatic system (or other area of the body) and an external drainage device. This device can be only temporarily located in the patient or can be implanted within the patient for longer periods of time. The physician can safely and reliably remove excess fluid from the body via the device and optionally inject other treatment agents.
    Type: Application
    Filed: February 24, 2022
    Publication date: June 9, 2022
    Applicant: NXT Biomedical, LLC
    Inventors: Robert S. Schwartz, Stanton J. Rowe, Alexander Siegel, Joseph Passman, Robert C. Taft, Glen Rabito
  • Patent number: 11344411
    Abstract: The present invention relates to devices and methods for improving the function of a defective heart valve, and particularly for reducing regurgitation through an atrioventricular heart valveā€”i.e., the mitral valve and the tricuspid valve. For a tricuspid repair, the device includes an anchor deployed in the tissue of the right ventricle, in an orifice opening to the right atrium, or anchored to the tricuspid valve. A flexible anchor rail connects to the anchor and a coaptation element on a catheter rides over the anchor rail. The catheter attaches to the proximal end of the coaptation element, and a locking mechanism fixes the position of the coaptation element relative to the anchor rail. Finally, there is a proximal anchoring feature to fix the proximal end of the coaptation catheter subcutaneously adjacent the subclavian vein. The coaptation element includes an inert covering and helps reduce regurgitation through contact with the valve leaflets.
    Type: Grant
    Filed: April 19, 2019
    Date of Patent: May 31, 2022
    Assignee: Edwards Lifesciences Corporation
    Inventors: Stanton J. Rowe, Robert S. Schwartz, Robert Van Tassel, Vivian Khalil, Erin M. Spinner, Neil S. Zimmerman, Alexander J. Siegel
  • Publication number: 20220088355
    Abstract: Methods and devices that prevent stasis in the LAA by either increasing the flow through the LAA or by closing off or sealing the LAA. Increasing the flow is accomplished through shunts, flow diverters, agitators, or by increasing the size of the ostium. Closing off the LAA is accomplished using seals or by cinching the LAA.
    Type: Application
    Filed: February 6, 2020
    Publication date: March 24, 2022
    Applicant: NXT Biomedical, LLC
    Inventors: Glen Rabito, Joseph Passman, Robert C. Taft, Stanton J. Rowe, Robert S. Schwartz, Alexander Siegel
  • Patent number: 11272877
    Abstract: Systems, methods and devices for controlled sympathectomy procedures for neuromodulation in the treatment of subjects having neoplastic conditions are disclosed. Systems, methods, and devices for interventionally treating a cancerous tumor and cancer related pain are disclosed.
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: March 15, 2022
    Assignee: Autonomix Medical, Inc.
    Inventors: Landy Toth, Robert S. Schwartz
  • Publication number: 20220031378
    Abstract: Compositions, systems, devices, and methods for performing precise chemical treatment of tissues are disclosed. Systems, devices, and methods for administering a chemical agent to one or more a precise regions within a tissue mass are disclosed. Compositions, systems, devices, and methods for treating targeted regions within a tissue mass are disclosed. Systems, devices, and methods for identifying, localizing, monitoring neural traffic in the vicinity of, quantifying neural traffic in the vicinity of, and mapping neural traffic near targeted regions within a tissue mass are disclosed.
    Type: Application
    Filed: October 19, 2021
    Publication date: February 3, 2022
    Inventors: Landy Toth, Robert S. Schwartz
  • Publication number: 20220016399
    Abstract: MVO is treated by introducing injectate into blood vessels affected by MVO at precise flow rates, while blocking retrograde flow, such that the natural pumping of the heart aids in forcing the injectate into the affected microvessels. Monitoring pressure distal of an occlusion balloon is used to determine treatment effectiveness and heart health.
    Type: Application
    Filed: September 30, 2021
    Publication date: January 20, 2022
    Applicant: CorFlow Therapeutics AG
    Inventors: Robert S. SCHWARTZ, Martin T. ROTHMAN, Jon H. HOEM
  • Patent number: 11185361
    Abstract: Compositions, systems, devices, and methods for performing precise chemical treatment of tissues are disclosed. Systems, devices, and methods for administering a chemical agent to one or more a precise regions within a tissue mass are disclosed. Compositions, systems, devices, and methods for treating targeted regions within a tissue mass are disclosed. Systems, devices, and methods for identifying, localizing, monitoring neural traffic in the vicinity of, quantifying neural traffic in the vicinity of, and mapping neural traffic near targeted regions within a tissue mass are disclosed.
    Type: Grant
    Filed: October 10, 2016
    Date of Patent: November 30, 2021
    Inventors: Landy Toth, Robert S. Schwartz
  • Publication number: 20210366620
    Abstract: Systems, methods and apparatus are included that are configured to model microvascular obstruction (MVO) in patients. According to one aspect of the present disclosure, a multi-scale model is configured to mimic myocardial microcirculation of coronary vessels. The model includes collaterals configured to provide alternative pathways possibly bypassing the MVO, and configured to model coronary artery compliance for spatially resolved fluid transport through the coronary vessels. The model is configured to simulate the MVO by increasing flow resistance in at least one of the modelled coronary vessels, or by blocking the at least one of the modelled coronary vessels completely. The model is also configured to mimic behavior of fluid transport in the coronary vessels during diagnostics or treatment, to design and optimize therapy protocols for the MVO.
    Type: Application
    Filed: May 31, 2019
    Publication date: November 25, 2021
    Applicants: CorFlow Therapeutics AG, Interstate University of Applied Sciences Buchs, University of Bern
    Inventors: Andre BERNARD, Peter HEEB, Cornelia NEF, Dominik OBRIST, Francesco CLAVICA, Sabrina FREY, Robert S. SCHWARTZ, Jon Helge HOEM, Oliver BLUDAU
  • Publication number: 20210361170
    Abstract: Methods and systems are provided for diagnosis and/or treatment of microvascular dysfunction, such as microvascular obstruction (MVO), in which the effects of collateral flow around a treatment site are addressed by injecting volumetric flows into a vessel using an infusion system to prevent or render negligible the collateral flow. Arterial pressures and fluidic flow rates sufficient to negate the collateral flow may be used to indicate the presence and/or severity of MVO for diagnostic and/or therapeutic purposes.
    Type: Application
    Filed: May 21, 2021
    Publication date: November 25, 2021
    Inventors: Robert S. SCHWARTZ, Jon Helge HOEM, Sabrina FREY, Oliver BLUDAU
  • Publication number: 20210346702
    Abstract: Systems and methods for controlling blood pressure by controlling atrial pressure and atrial stretch are disclosed. In some embodiments, a stimulation circuit may be configured to deliver a stimulation pulse to at least one cardiac chamber of a heart of a patient, and at least one controller may be configured to execute delivery of one or more stimulation patterns of stimulation pulses to the at least one cardiac chamber, wherein at least one of the stimulation pulses stimulates the heart such that an atrial pressure resulting from atrial contraction of an atrium overlaps in time a passive pressure build-up of the atrium, such that an atrial pressure of the atrium resulting from the stimulation is a combination of the atrial pressure resulting from atrial contraction and the passive pressure build-up and is higher than an atrial pressure of the atrium would be without the stimulation, and such that the blood pressure of the patient is reduced.
    Type: Application
    Filed: March 18, 2021
    Publication date: November 11, 2021
    Inventors: Yuval Mika, Darren Sherman, Robert S. Schwartz, Robert A. Van Tassel, Daniel Burkhoff
  • Publication number: 20210338240
    Abstract: Methods and devices for increasing oxygenation levels in the blood supply and thereby treating the condition of hypoxemia. Multiple approaches such as pressure reduction in the pulmonary circulatory system, reducing triggering mechanisms in the main pulmonary artery and restricting flow in the pulmonary circulatory system are disclosed. Interventions associated with those approaches can including shunting, restrictors, compliance devices, pharmacologic substances, etc.
    Type: Application
    Filed: July 14, 2021
    Publication date: November 4, 2021
    Applicant: NXT Biomedical, LLC
    Inventors: Stanton J. Rowe, Robert S. Schwartz, Glen Rabito, Robert C. Taft, Elliot Howard, Alexander Siegel, Joseph Passman
  • Patent number: 11154239
    Abstract: Systems, devices, and methods for performing precise treatment, mapping, and/or testing of tissues are disclosed. Systems, devices, and methods for administering an agent to one or more a precise regions within a tissue mass are disclosed. Systems, devices, and methods for treating targeted regions within a tissue mass are disclosed. Systems, devices, and methods for identifying, localizing, monitoring neural traffic in the vicinity of, quantifying neural traffic in the vicinity of, and mapping neural traffic near targeted regions within a tissue mass are disclosed.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: October 26, 2021
    Assignee: Autonomix Medical, Inc.
    Inventors: Landy Toth, Robert S. Schwartz
  • Patent number: 11135408
    Abstract: MVO is treated by introducing injectate into blood vessels affected by MVO at precise flow rates, while blocking retrograde flow, such that the natural pumping of the heart aids in forcing the injectate into the affected microvessels. Monitoring pressure distal of an occlusion balloon is used to determine treatment effectiveness and heart health.
    Type: Grant
    Filed: May 15, 2019
    Date of Patent: October 5, 2021
    Assignee: CorFlow Therapeutics AG
    Inventors: Robert S. Schwartz, Martin T. Rothman, Jon H. Hoem